In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Tri-Med Labs

This article was originally published in The Tan Sheet

Executive Summary

Tri-Med Labs: "Serious" deviations from GMP regs were documented by FDA investigators at Tri-Med's Somerset, N.J. facility, FDA says in a March 26 warning letter. The letter cites various problems in the firm's manufacture, processing, packing and holding of various drug products, causing the products to be considered adulterated under the FD&C Act. For example, Tri-vitamin Drops with Fluoride .25 mg Supplement for Infants contains levels of vitamins A and D and ascorbic acid exceeding the label claims...





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts